Antisense oligonucleotide compositions and methods for the modulation of JNK proteins

• US 6,221,850 B1
• Filed: 08/07/1998
• Issued: 04/24/2001
• Est. Priority Date: 08/13/1997
• Status: Expired due to Term

• Current Assignee: Ionis Pharmaceuticals, Inc.
• Original Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Inventors: McKay, Robert, Dean, Nicholas, Nero, Pamela Scott, Monia, Brett P., Gaarde, William A.
• Primary Examiner(s): Brusca, John S.
• Assistant Examiner(s): SHIBUYA, MARK LANCE
• Application Number:
  US09/130,616
• Time in Patent Office: 991 Days
• Field of Search: 435/6, 435/69.1, 435/91.1, 435/440, 435/325, 435/352, 435/353, 435/354, 435/366, 435/371, 435/375, 435/320.1, 435/183, 435/194, 536/23.1, 536/24.3, 536/24.31, 536/24.33, 536/24.5, 514/44
• US Class Current: 514/44.00A
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/334 Modified C
• CPC Class Codes: C12N 2310/3515 Lipophilic moiety, e.g. cholesterol
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.

Claims

1. An oligonucleotide comprising up to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence which specifically binds to a 3′

-untranslated region, an open reading frame region, or a translation initiation region of a nucleic acid encoding JNK1 protein (SEQ ID NO;

     164), a homolog of JNK1 (SEQ ID NO;

     165) or an alpha-2 (SEQ ID NO;

166), beta-1 (SEQ ID N;

167) or beta-2 (SEQ ID NO;

168) isoform thereof, and wherein said oligonucleotide modulates the expression of said JNK1 protein, said JNK1 homolog or said isoform thereof.

2. The oligonucleotide of claim 1 further comprising at least one lipophilic moiety which enhances the cellular uptake of said oligonucleotide.

5. The oligonucleotide of claim 1, 3 or 4 wherein at least one of said covalent linkages of said oligonucleotide is a modified covalent linkage.

6. The oligonucleotide of claim 1, 3 or 4 wherein at least one of said nucleotides has a modified nucleobase.

7. The oligonucleotide of claim 1, 3 or 4 wherein at least one of said nucleotides has a modified sugar moiety.

8. The oligonucleotide of claim 1, 3 or 4 wherein at least one of said covalent linkages of said oligonucleotide is a modified covalent linkage and at least one of said nucleotides has a modified sugar moiety.

9. The oligonucleotide of claim 1, 3 or 4 having at least two non-contiguous nucleotides having modified sugar moieties.

10. The oligonucleotide of claim 1, 3 or 4 having at least two non-contiguous nucleotides having modified sugar moieties, wherein at least one of said covalent linkages of said oligonucleotide is a modified covalent linkage and at least one of said nucleotides has a modified sugar moiety.

11. A pharmaceutical composition comprising the oligonucleotide of claim 1, 3 or 4 or a bioequivalent thereof, and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, further comprising one or more compounds from the list consisting of a stabilizing agent, a penetration enhancer, a carrier compound and a chemotherapeutic agent.

13. A pharmaceutical composition comprising a plurality of the oligonucleotides of claim 1, 3 or 4 or bioequivalents thereof, and a pharmaceutically acceptable carrier.

14. A method of treating a mouse, rat or human having, suspected of having or prone to having a hyperproliferative disease comprising administering to said mouse, rat or human a prophylactically or therapeutically effective amount of the pharmaceutical composition of claim 11.

15. A method of inhibiting the expression of a JNK protein in cells or tissues comprising contacting said cells or tissues with the oligonucleotide of claim 1, 3 or 4.

16. A method of inhibiting cell cycle progression in cultured cells or the cells of a mouse, rat or human comprising administering to said cells an effective amount of the oligonucleotide of claim 1, 3 or 4.

17. A method of inhibiting, in cultured cells or the cells of a mouse, rat or human, the phosphorylation of a protein phosphorylated by a JNK protein, wherein said method comprises administering to said cells an effective amount of the oligonucleotide of claim 1, 3 or 4.

18. A method of inhibiting, in cultured cells or the cells of a mouse, rat or human, the expression of a cellular protein that promotes one or more metastatic events, wherein said method comprises administering to said cells an effective amount of the oligonucleotide of claim 1, 3 or 4.

19. The oligonucleotide of claim 1, 3 or 4 wherein said JNK protein is that of a mouse, rat or human.

20. The oligonucleotide of claim 6 wherein said modified nucleobase is 5-methylcytosine.

21. A method of inhibiting the growth of a tumor in a mouse, rat or human comprising administering to said mouse, rat or human an effective amount of the pharmaceutical composition of claim 11.

22. A method of inhibiting the growth of a tumor in a mouse, rat or human comprising administering to said mouse, rat or human an effective amount of the pharmaceutical composition of claim 12.

3. An oligonucleotide comprising up to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence which specifically binds to a JNK2 homolog (SEQ ID NO:

170) or an alpha-1 (SEQ ID NO;

171), beta-1 (SEQ ID NO;

172) or beta-2 (SEQ ID NO;

173) isoform thereof and wherein said oligonucleotide inhibits the expression of said JNK2 protein, said JNK2 homolog or said isoform thereof.

4. An oligonucleotide comprising up to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence which specifically binds to a 3′

-untranslated region, an open reading frame region, a 5′

-untranslated region or a translation initiation region of a nucleic acid encoding a JNK3 protein (SEQ ID NO;

     174), a JNK3 homolog (SEQ ID NO;

175 or SEQ ID NO;

176) or an alpha-1 (SEQ ID NO;

177) or alpha-2 (SEQ ID NO;

178) isoform thereof and wherein said oligonucleotide modulates the expression of said JNK3 protein, said JNK3 homolog or said isoform thereof.

23. An antisense oligonucleotide up to 30 nucleobase in length comprising at least an 8-nucleobase portion of SEQ ID NO:

29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or 41, wherein said antisense oligonucleotide inhibits JNK2 protein expression.